# US 10,308,647 B2 · Fused imidazole derivatives as IDO/TDO inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,308,647 B2
- Document ID: US10308647B2
- Status: Granted
- Kind: B2
- Application number: 15/336,993
- Filed: 2016-10-28
- Published: 2017-05-04
- Granted: 2019-06-04
- Earliest claimed: 2015-10-29
- Assignees: SciFluor Life Sciences, Inc.
- Applicants: SciFluor Life Sciences, Inc.
- Inventors: Ben C. Askew; Takeru Furuya
- Web page: https://patentgrep.com/patent/US10308647B2

## CPC

- C07D 471/04: Ortho-condensed systems
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present application relates to compounds and methods for the modulation (e.g., inhibition) of the enzyme indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase (IDO/TDO), and methods of treating diseases and disorders in which IDO/TDO plays a role. The present application provides compounds of Formula (I) or (II):

## Claims

### Claim 1

A compound of Formula (I)
or a pharmaceutically acceptable salt or solvate thereof, wherein:
W1 is CR1 or N;
W2 is CR2 or N;
W3 is CR3 or N;
W4 is CR4 or N;
R1, R2, R3, and R4 are each independently H, OH, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy;
Z1, Z2, and Z3 are each independently a single bond, CHRZ, or CH2CHRZ, wherein one of Z1, Z2, and Z3 is CHRZ, or one of Z1, Z2, and Z3 is CH2CHRZ;
each RZ is independently H, OH, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy;
Y is H, C1-C4 alkyl, or C1-C4 haloalkyl;
n is 0, 1, 2, or 3;
R5 is OH, halogen, C1-C4 alkoxy, or C1-C4 haloalkoxy;
R6 is H, OH, halogen, C1-C4 alkoxy, or C1-C4 haloalkoxy; and
R7 and R8 are each independently H, halogen, C1-C4 alkyl, or C1-C4 haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein W1 is CR1, W2 is CR2, W3 is CR3, W4 is CR4, and R1, R2, R3, and R4 are each H.

### Claim 3 (depends on 1)

The compound of claim 1, wherein W1 is CR1, W2 is CR2, W3 is CR3, W4 is CR4, and at least one of R1, R2, R3, and R4 is OH, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy.

### Claim 4 (depends on 1)

The compound of claim 1, wherein one of W1, W2, W3, and W4 is N.

### Claim 5 (depends on 1)

The compound of claim 1, wherein one of Z1, Z2, and Z3 is CH2CHRZ.

### Claim 6 (depends on 1)

The compound of claim 1, wherein one of Z1, Z2, and Z3 is CHRZ.

### Claim 7 (depends on 1)

The compound of claim 1, wherein RZ is H.

### Claim 8 (depends on 1)

The compound of claim 1, wherein RZ is OH, halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or C1-C4 haloalkoxy.

### Claim 9 (depends on 1)

The compound of claim 1, wherein n is 0.

### Claim 10 (depends on 1)

The compound of claim 1, wherein n is 1.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R5 is OH.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R5 is halogen.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is of Formula (Ib), (Ic), or (Id)
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 14 (depends on 1)

The compound of claim 1, selected from
wherein Cy represents cyclohexyl.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient.